PLC receives Brazilian government approval to market RenalGuard System

NewsGuard 100/100 Score

PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that it had received approval from the Brazilian government  to market its innovative RenalGuard System™ in that country.  PLC's exclusive distributor in Brazil, DISCOMED Comercio de Produtos Hospitalares Ltda., Porto Alegre, Brazil, secured approval for both the RenalGuard® system and its single use sets through ANVISA, the Brazilian registration authority. Discomed is now beginning launch efforts in Brazil, including placing an initial stocking order, scheduling training sessions and promoting RenalGuard to medical professionals in the market.  

Brazil is the fifth largest country in the world, by population, and has a rapidly growing healthcare market. PLC appointed Discomed as its exclusive distributor for this region in late 2009.

"Approval to sell RenalGuard in Brazil is yet another significant development for PLC," said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems. "Brazil is a pivotal country in South America, where new medical technologies are often first demonstrated, and we're delighted that Discomed is now ready to work with us to launch RenalGuard formally in this market.  Following our launch in Israel earlier this month, today's announcement will certainly help drive increased adoption of RenalGuard worldwide."

Source:

PLC Systems Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.